Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15306 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Signe Foghsgaard und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes, Gestational, Diabetes Mellitus, Type 2, Prediabetic State. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Aase og Ejnar Danielsens Fond, Danish Diabetes and Endocrine Academy, Fonden til Laegevidenskabens Fremme.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
We investigated the effect of 52‐week treatment with liraglutide, a glucagon‐like peptide 1 receptor agonist, on glucose tolerance and incretin effect in women with previous gestational diabetes mellitus (pGDM). Materials and Methods Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks. Participants underwent oral glucose tolerance test (OGTT) and isoglycaemic intravenous glucose infusion at baseline and at 52 weeks, and an additional OGTT after the drug wash‐out.
Results
In total, 104 women [age: mean ± SD, 38 ± 5 years; fasting plasma glucose (FPG): 5.5 ± 0.4 mmol/L; glycated haemoglobin (HbA1c): 33 ± 4 mmol/mol, bodyweight: 88.2 ± 14.8 kg, body mass index: 31.1 ± 4.3 kg/m 2 ] were assigned to liraglutide (n = 49) or placebo (n = 55). Estimated treatment difference (ETD) for area under curve during OGTT was −173 (95% confidence interval −250 to −97) mmol/L × min, p < .0001, but after wash‐out the difference disappeared [ETD 58 (−30 to 146) mmol/L × min, p = .536]. Liraglutide reduced FPG [ETD −0.2 (−0.4 to −0.1) mmol/L, p = .018], HbA1c [−2.2 (−3.5 to −0.8) mmol/mol, p = .018] and bodyweight [−3.9 (−6.2 to −1.6) kg, p = .012]. No change in the incretin effect was observed. The number of women with prediabetes was reduced from 64% to 10% with liraglutide vs. 50% with placebo [adjusted odds ratio 0.10 (0.03‐0.32), p = .002].
Conclusions
Treatment with liraglutide for 52 weeks improved glucose tolerance, FPG, HbA1c and bodyweight in women with overweight/obesity and pGDM. Progression to prediabetes while on drug was markedly reduced, but after a 1‐week drug wash‐out, the effect was lost.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark.
- Department of Gynaecology and Obstetrics, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
- Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
- Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Center for Pregnant Women with Diabetes, Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Signe Foghsgaard, Louise Vedtofte, Emilie S Andersen, Julie L Forman, Elisabeth R Mathiesen, Jens J Holst, Filip K Knop, Tina Vilsbøll
Förderung
- Aase og Ejnar Danielsens Fond
- Danish Diabetes and Endocrine Academy
- Fonden til Laegevidenskabens Fremme
- Novo Nordisk Fonden
- Novo Nordisk Pharma investigator-initiated study supported by unrestri
- Fonden til Lægevidenskabens Fremme
Zitieren
APA
Foghsgaard, S., Vedtofte, L., Andersen, E. S., Bahne, E., Andreasen, C., Sørensen, A. L., Forman, J. L., Mathiesen, E. R., Svare, J. A., Clausen, T. D., Damm, P., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2024). Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15306
Vancouver
Foghsgaard S, Vedtofte L, Andersen ES, Bahne E, Andreasen C, Sørensen AL, et al. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15306
BibTeX
@article{Foghsgaard2024,
author = {Foghsgaard, Signe and Vedtofte, Louise and Andersen, Emilie S and Bahne, Emilie and Andreasen, Camilla and Sørensen, Anne L and Forman, Julie L and Mathiesen, Elisabeth R and Svare, Jens A and Clausen, Tine D and Damm, Peter and Holst, Jens J and Knop, Filip K and Vilsbøll, Tina},
title = {Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15306}
}
EUVIMED